# VivoSim Labs, INC. (VIVS) — delisting/forced [announced]
Source: SEC API (secapi.ai) · situation sit_4fc06f37c01a301b9313 · retrieved 2026-08-11T15:50:03.685Z

## Overview
VivoSim Labs, Inc. is a biological products company (formerly known as Organovo Holdings, Inc.) that develops tissue engineering and regenerative medicine technologies.

On July 20, 2026, VivoSim Labs, Inc. received a notice from Nasdaq indicating that the company failed to maintain the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company's Form 10-K for the period ended March 31, 2026 reported stockholders' equity of $(1,099,000), and the company did not meet alternative requirements based on market value of listed securities or net income from continuing operations. VivoSim has 45 calendar days from July 20, 2026 (until September 3, 2026) to submit a plan to regain compliance. If Nasdaq accepts the plan, the company may receive an extension of up to 180 calendar days (until January 16, 2027) to achieve compliance. However, as of the filing date, the company's stockholders' equity exceeded $2.5 million due to a $5.0 million milestone payment from Eli Lilly, a private placement closing on July 17, 2026 that raised approximately $4.0 million, and warrant exercises that increased stockholders' equity by approximately $5.1 million.

## Terms
- Counterparty: The Nasdaq Stock Market LLC

## Key dates
- Announced 2026-07-24 · Expiry 2026-09-03

## Timeline
- 2026-07-24 · 8-K (0001213900-26-081377): 8-K - VivoSim Labs, INC. — *VivoSim Labs, Inc. is a biological products company (formerly known as Organovo Holdings, Inc.) that develops tissue engineering and regenerative medicine technologies.* On July 20, 2026, VivoSim Labs, Inc. received a notice from Nasdaq indicating that the company failed to maintain the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company's Form 10-K for the period ended March 31, 2026 reported stockholders' equity of $(1,099,000), and the company did not meet alternative requirements based on market value of listed securities or net income from continuing operations. VivoSim has 45 calendar days from July 20, 2026 (until September 3, 2026) to submit a plan to regain compliance. If Nasdaq accepts the plan, the company may receive an extension of up to 180 calendar days (until January 16, 2027) to achieve compliance. However, as of the filing date, the company's stockholders' equity exceeded $2.5 million due to a $5.0 million milestone payment from Eli Lilly, a private placement closing on July 17, 2026 that raised approximately $4.0 million, and warrant exercises that increased stockholders' equity by approximately $5.1 million.
  https://www.sec.gov/Archives/edgar/data/1497253/0001213900-26-081377.txt

## Citations
- 0001213900-26-081377 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026081377